News Release

Tarantula toxins converted to painkillers

It turns out that peptide toxins isolated from the venom of some animals -- such as the Peruvian green velvet tarantula -- can be beneficial when used to target neural receptors to reduce the sensation of pain.

Peer-Reviewed Publication

Biophysical Society

Peptide Toxin Isolated from the Peruvian Green Velvet Tarantula

image: This is the peptide toxin (blue) isolated from the Peruvian green velvet tarantula binds to neuronal cell membranes and inhibits the pain receptor NaV 1.7 (orange) at the cell membrane surface. view more 

Credit: Henriques

WASHINGTON, D.C., Feb. 28, 2016 -- When venom from animals such as spiders and snakes is injected via a bite or harpoon, the cocktail of toxins delivered to its victim tends to cause serious reactions that, if untreated, can be lethal. But even venom has a therapeutic upside: Individual peptide toxins are being tapped to target receptors in the brain to potentially serve as painkillers.

Millions of people live with chronic and neuropathic pain, in large part because current treatments often provide limited pain relief, have a heavy profile of soporific side effects and can be extremely addictive. So researchers around the globe are chasing down potential new therapeutic agents and working to gain a better understanding of how molecules with painkiller activity function. This will lead to alternative painkillers -- and possibly improve the quality of life for people who suffer from chronic pain.

“Our group is specifically interested in understanding the mode of action of this toxin to gain information that can guide us in the design and optimization of novel pain therapeutics,” said Sónia Troeira Henriques, senior research officer at the University of Queensland’s Institute for Molecular Bioscience. Her recent work was published in the Biophysical Journal on Feb. 16, 2016.

How does ProTx-II work? “It binds to the pain receptor located within the membrane of neuronal cells, but the precise peptide-receptor binding site and the importance of the cell membrane in the inhibitory activity of ProTx-II is unknown,” explained Henriques.

So the group zeroed in on its structure-activity relationship by “exploring the structure, the membrane-binding properties, and the inhibitory activity of ProTx-II and a series of analogues,” she added.

Nuclear magnetic resonance (NMR) spectroscopy enables 3-D characterization of the structure of this peptide, which allows the group to explore whether it’s important for its ability to inhibit the pain receptor.

They also use surface plasmon resonance and fluorescence methodologies, as well as molecular simulations, to further characterize the interactions between the peptide and the neuronal cell membrane and to identify the molecular properties of the peptide involved in the interaction and inhibition with the pain receptor.

“Our results show that the cell membrane plays an important role in the ability of ProTx-II to inhibit the pain receptor. In particular, the neuronal cell membranes attract the peptide to the neurons, increase its concentration close to the pain receptors, and lock the peptide in the right orientation to maximize its interaction with the target,” said Henriques.

The group’s work is the first to describe the importance of the membrane-binding properties of ProTx-II for its potency as an inhibitor of Nav 1.7, an important pain receptor. “Until now, studies characterizing the inhibitory activity of venom toxins have ignored the potential role of the cell membrane in their potency and activity,” she noted.

Beyond Nav 1.7, “other voltage-gated ion channels are located at the cell membrane and involved in a range of physiological processes such as muscle and nerve relaxation, regulation of blood pressure, and sensory transduction,” Henriques pointed out. “Their ‘faulty’ activity is, however, associated with several disorders, so other ion channels are actively being pursued as drug targets for the treatment of neuromuscular disease, neurological disorders, and inflammatory and neuropathic pain.”

Based on the group’s findings, they’re now designing new toxins with greater affinity for the cell membrane and fewer side effects.

“Our work creates an opportunity to explore the importance of the cell membrane in the activity of peptide toxins that target other voltage-gated ion channels involved in important disorders,” said Henriques.

The article, “Structure-Activity Relationship Studies Reveal that the Spider Toxin Protx-II has Unusual Membrane-Binding Properties and Inhibits NAV1.7 Channel at the Membrane Surface” is authored by Sonia Troeira Henriques, David J. Craik and Christina I. Schroeder, and was published in the Biophysics Journal on Feb. 16, 2016. It can be accessed at http://www.cell.com/biophysj/fulltext/S0006-3495%2815%2901660-4.

###

ABOUT THE SOCIETY

The Biophysical Society, founded in 1958, is a professional, scientific Society established to encourage development and dissemination of knowledge in biophysics. The Society promotes growth in this expanding field through its annual meeting, monthly journal, and committee and outreach activities. Its 9,000 members are located throughout the U.S. and the world, where they teach and conduct research in colleges, universities, laboratories, government agencies, and industry. For more information on the Society visit http://www.biophysics.org


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.